Jia Luo

Nov 16, 2024 | mdpi.com | Jia Luo |Jingxian Li |Weijing Wang |Ronghui Zhang

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jul 9, 2024 | medscape.com | Jacob Sands |Jia Luo

closePlease confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jacob Sands, MD: Hello. I'm Dr Jacob Sands. Welcome to Season 3 of the Medscape InDiscussion: Lung Cancer podcast series.

Jun 10, 2024 | thelancet.com | Jia Luo |Liza Villaruz

Despite rat sarcoma virus (RAS) oncogenes being the first identified, RAS-driven cancers have remained one of the greatest challenges in oncological drug development.

Apr 30, 2024 | mdpi.com | Bei Yan |Jia Luo |Min Zhang |Yi Zhang

All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.

Jan 31, 2024 | future-science.com | Jia Luo

PD-1 blockade is now routine for nearly all patients with non-small lung cancer. However, the proper investigation of alternative explanations and the cause remains not intuitive for many clinicians. We present a case of a patient who benefitted from PD-1 blockade for more than a year, but later developed what was initially suspected to be radiological progression.